Roche reported a 7% year-over-year decline in diagnostics sales in Q1 2026, attributing headwinds primarily to ongoing healthcare pricing reforms in China. At constant exchange rates, diagnostics sales rose, but the company pointed to a negative impact on core lab results tied to the policy changes. Executives said pricing reforms drove a CHF 60 million drag on diagnostics in the quarter, with China-specific sales down 14%. Separately, the firm cited a weaker respiratory season affecting molecular lab and near-patient care segments by about CHF 40 million. Roche also discussed a recently announced acquisition of SAGA Diagnostics, highlighting that its Pathlight minimal residual disease testing platform will be fully integrated into Foundation Medicine. The MRD move signals an effort to strengthen oncology monitoring and align diagnostics assets with pharma-adjacent companion strategies. Overall, Roche confirmed its outlook for full-year sales growth at constant exchange rates while navigating pricing volatility, which remains a dominant driver of near-term performance for global diagnostics franchises.